ValuEngine upgraded shares of CymaBay Therapeutics (NASDAQ:CBAY) from a sell rating to a hold rating in a research note published on Friday.
Several other research analysts have also commented on CBAY. Piper Jaffray Companies reiterated a buy rating and set a $12.00 price objective on shares of CymaBay Therapeutics in a research note on Friday, October 27th. Oppenheimer set a $15.00 target price on shares of CymaBay Therapeutics and gave the stock a buy rating in a research report on Monday, October 30th. Cantor Fitzgerald reissued a buy rating and set a $16.00 target price on shares of CymaBay Therapeutics in a research report on Wednesday, November 8th. HC Wainwright reissued a buy rating and set a $12.00 target price on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Finally, Leerink Swann reissued a buy rating and set a $16.00 target price on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. CymaBay Therapeutics currently has an average rating of Buy and a consensus target price of $16.56.
CymaBay Therapeutics (CBAY) opened at $12.03 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39. CymaBay Therapeutics has a 52 week low of $1.92 and a 52 week high of $12.60.
In other CymaBay Therapeutics news, Director Kurt Von Emster sold 97,639 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $12.22, for a total transaction of $1,193,148.58. Following the sale, the director now owns 90,000 shares of the company’s stock, valued at approximately $1,099,800. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders have sold 647,086 shares of company stock worth $6,726,633. 15.10% of the stock is owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. purchased a new stake in shares of CymaBay Therapeutics in the 4th quarter valued at $115,000. GSA Capital Partners LLP purchased a new stake in shares of CymaBay Therapeutics in the 3rd quarter valued at $1,218,000. Iguana Healthcare Management LLC boosted its holdings in shares of CymaBay Therapeutics by 138.1% in the 3rd quarter. Iguana Healthcare Management LLC now owns 250,000 shares of the biopharmaceutical company’s stock valued at $2,015,000 after acquiring an additional 145,000 shares during the last quarter. Crestline Management LP purchased a new stake in shares of CymaBay Therapeutics in the 3rd quarter valued at $841,000. Finally, Perceptive Advisors LLC purchased a new stake in shares of CymaBay Therapeutics in the 3rd quarter valued at $18,948,000. 54.70% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.com-unik.info/2018/02/05/cymabay-therapeutics-cbay-upgraded-to-hold-at-valuengine.html.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.